INT10094

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1987
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 36
Total Number 38
Disease Relevance 20.45
Pain Relevance 6.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (ALPP)
Anatomy Link Frequency
Plasma 1
white blood cell 1
liver 1
arm 1
skin 1
ALPP (Homo sapiens)
Pain Link Frequency Relevance Heat
Paracetamol 80 99.98 Very High Very High Very High
Pain 62 99.44 Very High Very High Very High
imagery 29 97.12 Very High Very High Very High
Endogenous opioid 2 96.64 Very High Very High Very High
Inflammation 79 95.84 Very High Very High Very High
Potency 3 94.16 High High
Bile 29 93.84 High High
fibrosis 32 92.20 High High
Prostatitis 2 91.16 High High
cytokine 8 83.52 Quite High
Disease Link Frequency Relevance Heat
Hypophosphatasia 96 99.84 Very High Very High Very High
Multiple Myeloma 23 99.84 Very High Very High Very High
Ovarian Cancer 20 99.72 Very High Very High Very High
Disease 154 99.66 Very High Very High Very High
Disorder Of Lipid Metabolism 5 99.56 Very High Very High Very High
Pain 65 99.44 Very High Very High Very High
Phosphate Metabolism Disorders 68 99.36 Very High Very High Very High
Body Weight 46 98.96 Very High Very High Very High
Toxicity 30 98.44 Very High Very High Very High
Nicotine Addiction 69 97.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In contrast, indomethacin inhibited ALP on smooth surfaces and stimulated ALP on rough.
Negative_regulation (inhibited) of ALP
1) Confidence 0.37 Published 2008 Journal J Oral Implantol Section Abstract Doc Link 19133484 Disease Relevance 0.52 Pain Relevance 0.10
Her T-ALP and uNTX levels rapidly decreased and her bone pain improved within a few months, and this remission in T-ALP level, uNTX level and bone pain was maintained for more than one year.
Negative_regulation (decreased) of T-ALP associated with pain
2) Confidence 0.36 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2887900 Disease Relevance 0.76 Pain Relevance 0.58
Similarly, K+-treated OS cells exhibited decreased ALP activity in a dose-dependent manner (1.8, 2.1, 3.7, 7.1-fold decreased activity for increasing K+ concentrations, Fig. 8A, p<0.008).
Negative_regulation (decreased) of ALP
3) Confidence 0.35 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2581599 Disease Relevance 0.06 Pain Relevance 0
During OS differentiation, ALP activity and calcium content were also significantly reduced.
Negative_regulation (reduced) of ALP
4) Confidence 0.31 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2581599 Disease Relevance 0 Pain Relevance 0.11
Ouabain-treated cells had 3.9-fold decreased ALP activity compared to untreated OS cells (Fig. 8A, p<0.001).
Negative_regulation (decreased) of ALP
5) Confidence 0.31 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2581599 Disease Relevance 0.06 Pain Relevance 0
Proenkephalin-derived peptides have been shown to inhibit alkaline phosphatase activity, another marker of bone formation, in the murine cell line ROS-17/2.8.
Negative_regulation (inhibit) of alkaline phosphatase
6) Confidence 0.30 Published 2000 Journal Neuroendocrinology Section Abstract Doc Link 11025413 Disease Relevance 0.62 Pain Relevance 0.36
other alkaline phosphatase activity and eventually also decrease
Negative_regulation (decrease) of alkaline phosphatase
7) Confidence 0.26 Published 2006 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC1559920 Disease Relevance 0.71 Pain Relevance 0.03
Determination of PLAP/PLAP-like activity using immunoassays could
Negative_regulation (Determination) of PLAP
8) Confidence 0.25 Published 2006 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC1559920 Disease Relevance 1.33 Pain Relevance 0.09
Acetaminophen inhibited both basal and estradiol-induced alkaline phosphatase activity in Ishikawa cells in a concentration-dependent manner.
Negative_regulation (inhibited) of alkaline phosphatase associated with paracetamol
9) Confidence 0.25 Published 2003 Journal Toxicol. Sci. Section Abstract Doc Link 12604834 Disease Relevance 0.16 Pain Relevance 0.74
Acetaminophen also augmented 4-hydroxy-tamoxifen reduction of alkaline phosphatase activity.
Negative_regulation (reduction) of alkaline phosphatase associated with paracetamol
10) Confidence 0.25 Published 2003 Journal Toxicol. Sci. Section Abstract Doc Link 12604834 Disease Relevance 0.23 Pain Relevance 0.95
High concentrations of acetaminophen (>/=0.5 mM) induced lactate dehydrogenase release from cells and reduced the amount of cellular protein in culture dishes, indicating some acetaminophen-induced reduction of alkaline phosphatase activity might be attributed to toxic effects.
Negative_regulation (reduction) of alkaline phosphatase associated with paracetamol
11) Confidence 0.25 Published 2003 Journal Toxicol. Sci. Section Abstract Doc Link 12604834 Disease Relevance 0.23 Pain Relevance 1.02
However, lower concentrations of acetaminophen significantly reduced alkaline phosphatase activity in the absence of detectable toxicity.
Negative_regulation (reduced) of alkaline phosphatase associated with toxicity and paracetamol
12) Confidence 0.25 Published 2003 Journal Toxicol. Sci. Section Abstract Doc Link 12604834 Disease Relevance 0.23 Pain Relevance 0.96
During chronic treatment with salmon calcitonin, alkaline phosphatase activity and urinary hydroxyproline excretion decrease on an average of 50% in patients with Paget's disease.
Negative_regulation (decrease) of alkaline phosphatase associated with disease
13) Confidence 0.25 Published 1991 Journal Calcif. Tissue Int. Section Abstract Doc Link 1933617 Disease Relevance 0.60 Pain Relevance 0.13
Ouabain treatment decreased ALP by 2.1-fold and BSP by 34.9-fold (p<0.002, Fig. 7A,B).
Negative_regulation (decreased) of ALP
14) Confidence 0.23 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2581599 Disease Relevance 0.08 Pain Relevance 0
Treatment with 40, 60, and 80 mM K+ decreased ALP by 1.4-, 1.3-, and 4.6-fold, respectively, and BSP by 2.7-, 10.3-, and 69.8-fold, respectively (p<0.002), compared to untreated OS samples (Fig. 7A,B).
Negative_regulation (decreased) of ALP
15) Confidence 0.23 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2581599 Disease Relevance 0.08 Pain Relevance 0
Alkaline phosphatase, gamma-glutamyl transferase, and bilirubin levels are often decreased with no known undesirable effects.
Neg (no) Negative_regulation (decreased) of Alkaline phosphatase
16) Confidence 0.22 Published 1987 Journal Am. J. Med. Section Abstract Doc Link 3318450 Disease Relevance 0.83 Pain Relevance 0.11
propose a normal hPLAP/PLAP-like enzyme activity cutoff value
Negative_regulation (value) of hPLAP
17) Confidence 0.22 Published 2006 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC1559920 Disease Relevance 0.16 Pain Relevance 0
developed for determining hPLAP/PLAP-like enzyme activity.
Spec (determining) Negative_regulation (determining) of hPLAP
18) Confidence 0.22 Published 2006 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC1559920 Disease Relevance 0.12 Pain Relevance 0.04
Plasma alkaline phosphatase (U/l, mean +/- SEM) decreased from 263 +/- 34 to 110 +/- 8 (1 h infusion), from 251 +/- 26 to 102 +/- 9 (4 h), from 237 +/- 23 to 95 +/- 9 (8 h) and from 256 +/- 29 to 97 +/- 7 (24 h), from day 0 to day 180 respectively (all p < 0.001).
Negative_regulation (decreased) of Plasma alkaline phosphatase in Plasma
19) Confidence 0.19 Published 1992 Journal Schweiz Med Wochenschr Section Abstract Doc Link 1462150 Disease Relevance 0.33 Pain Relevance 0.09
A subset analysis of patients included in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT) showed that when compared with placebo, annual IV infusion of zoledronic acid induced a median decrease of 50% in beta-C-terminal telopeptides of Type 1 collagen (beta-CTx) and a 30% decrease in bone-specific alkaline phosphatase (ALP) in 604 patients (305 on placebo and 299 on zoledronic acid), and a 56% decrease in procollagen Type 1 amino-terminal peptides (PINP) in 1245 patients (627 on placebo and 618 on zoledronic acid).
Negative_regulation (decrease) of ALP
20) Confidence 0.13 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998805 Disease Relevance 0.32 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox